CD8A and neoplasm: Immune profiling of 393P tumor tissues at the experimental endpoints or after 2 weeks of treatment showed an increase in total CD8+ T cells only when tumors were treated with AZD6244 monotherapy or in combination with anti-PD-L1 (Fig. 2e and Supplementary Fig. 3b).